

Integrum secures top sponsorship title at the Global Collaborative Congress on Osseointegration exclusively for the next three years

Mölnadal, Sweden, August 13, 2025 – Integrum AB (publ) (Nasdaq First North Growth Market: INTEG B), the provider of the OPRA™ Implant System, has announced that it has secured the exclusive title of Legacy Sponsor – the highest level of sponsorship – for the Global Collaborative Congress on Osseointegration (GCCO) annual meeting, held in Charlotte, North Carolina, USA.

This multi-year sponsorship grants Integrum exclusive top-tier recognition for the next three years and underscores the company's long-standing commitment to clinical education, surgical innovation, and international collaboration in the field of osseointegration, known as bone-anchored prosthetics. As a Legacy Sponsor, Integrum will continue to support the global limb loss community by fostering research, advancing outcomes, and engaging cross-disciplinary education.

"We're proud to serve as top sponsor of the GCCO conference. This partnership reflects our shared commitment to facilitating innovation and fostering global collaboration to expand limb loss care. We believe in the power of shared knowledge and scientific evidence to drive long-term impact," said Jeffrey Zanni, President of Integrum Inc.

The GCCO conference brings together leaders in surgical innovation, rehabilitation, prosthetics and clinical research to further the progress being made in the field of bone-anchored prosthetics.

"Integrum's support has been instrumental in driving forward the mission of GCCO—to unite experts across borders to advance limb loss care. Their commitment to innovation and education elevates the quality of our conversations and enables us to continue improving outcomes for amputees worldwide," said Dr. Joseph Hsu, conference chair and orthopedic trauma surgeon.

Integrum's top sponsorship reflects its mission to provide freedom of mobility for every person by driving improved outcomes and greater access to advanced prosthetic solutions. The company remains committed to supporting GCCO's mission and upholding shared objectives within the osseointegration space.

For more information about Integrum or the OPRA™ Implant System, visit <https://integrum.se/>.

For registration and more information about the GCCO conference visit <https://whova.com/portal/registration/1alq-wqaCdERx3smTUms/>.

For more information, please contact:

Jeffrey Zanni, President US
Email: Jeff.Zanni@integrum.se
Phone: +1 617-839-1600

Jörgen Svanström, CFO
Mobil: +46 (0) 7073 496 60,
Email: jorgen.svanstrom@integrum.se

Certified Adviser

The Company's Certified Adviser is DNB Carnegie Investment Bank AB.

About Integrum

Integrum AB is a publicly traded company (INTEG B: Nasdaq First North Growth Market) based outside of Gothenburg, Sweden, with a U.S. subsidiary in San Francisco. Since 1990, its OPRA™ Implant System has helped improve the quality of life for hundreds of people who are amputees by directly attaching a prosthesis to the bone and musculoskeletal system, therefore eliminating the need for a socket. Based on osseointegration, the bone-anchored implant system offers a range of benefits, including improved mobility and function, enhanced comfort, reduced pressure, a stable attachment and more. The OPRA™ Implant System was approved by the U.S. Food and Drug Administration (FDA) in 2020 and is the only FDA-approved bone-anchored implant system specifically designed for use in amputees available in the U.S. Today, Integrum continues to perform research and develop custom-made medical device solutions in close collaboration with scientists and clinicians. To learn more, please visit <https://integrum.se/>.